Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05953740 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05953740 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 17 participants.
The verdict
NCT05953740, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the administration of MK-5720 is safe and well tolerated.
Interventions
- DRUG MK-8189
- DRUG Placebo to MK-8189
- DRUG MK-5720
- DRUG Placebo to MK-5720
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05953740
The ClinicalTrials.gov registry entry for NCT05953740 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MK-8189 is the first listed.
NCT05953740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05953740 about?
NCT05953740 is a clinical study titled "A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the ...
What is the current status of trial NCT05953740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-09-15. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT05953740?
The interventions under investigation include: MK-8189 (DRUG), Placebo to MK-8189 (DRUG), MK-5720 (DRUG), Placebo to MK-5720 (DRUG).
Who is sponsoring clinical trial NCT05953740?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.